Patanjali’s Coronil gets Ayush Ministry certification as per WHO scheme

PTI New Delhi | Updated on February 19, 2021

Yoga Guru Swami Ramdev with Union Minister of Road Transport and Highways Nitin Gadkar, Union Minister for Health and Family Welfare Dr. Harshvardhan, and Achariya Balakrishna at the launch of the first evidence-based medicine for Covid-19

Company claimed that it is the first evidence-based medicine to fight Covid-19

Haridwar-based Patanjali Ayurved on Friday said Coronil has now received certification from Ayush Ministry as per World Health Organization (WHO) certification scheme.

The company claimed that it is the first evidence-based medicine to fight Covid-19.

The medicine was launched here at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

“Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme,” said Patanjali in a statement.

Under CoPP, Coronil can now be exported to 158 countries.

ALSO READ Madras HC sets aside order restraining Patanjali from using ‘Coronil’ trademark

Commenting on the development Swami Ramdev said, Coronil will help the humanity while providing affordable treatment based on naturopathy.

On the basis of presented data, the Ministry of Ayush has recognised Coronil Tablet as a medicine for “supporting measure in COVID-19.” Patanjali had earlier introduced Ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak.

ALSO READ Patanjali net rises 22% to ₹425 cr in 2019-20

However, it had to face severe criticism as it lacked scientific evidence. Then, the Ayush Ministry had indicated it as “Immuno-booster” only.

Coronil is developed by Patanjali Research Institute. It had started work for an Ayurvedic remedy for Covid-19 in January 2020.

Published on February 19, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like